avizakimab   Click here for help

GtoPdb Ligand ID: 12270

Synonyms: BOS 161721 | BOS161721
Compound class: Antibody
Comment: Avizakimab (BOS161721; Boston Pharmaceuticals) is a humanized anti-IL-21 antibody that inhibits IL-21 bioactivity. It was developed for potential to treat systemic lupus erythematosus (SLE), an auotimmune condition in which IL-21 is implicated as a driving factor [3-5]. IL-21 has been explored as a therapeutic target in a range of autoimmune disease models (SLE, rheumatoid arthritis, type 1 diabetes and psoriasis). Peptide sequences for avizakimab are claimed in Boston Pharmaceuticals' patent US10022443B2 [1].
Selectivity at ligand targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
IL-21 Hs Antibody Binding 10.0 – 12.0 pKd - 1
⤷ pKd 10.0 – 12.0 (Kd 1x10-10 – 1x10-12 M) [1]
Description: Estimated binding affinitiy, based on patent claims